S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Asian markets sink, with Japan’s Nikkei down 3.5%, as Mideast tensions flare
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$145.74
+0.7%
$156.32
$143.13
$175.97
$351.20B0.537.25 million shs9.87 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$102.00
-1.4%
$100.19
$62.55
$144.43
$39.05B1.624.18 million shs1.80 million shs
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.22%-3.61%-7.65%-10.18%-10.09%
Moderna, Inc. stock logo
MRNA
Moderna
-0.34%-3.45%-0.79%+4.41%-27.48%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.8712 of 5 stars
3.23.04.23.93.02.51.9
Moderna, Inc. stock logo
MRNA
Moderna
3.7426 of 5 stars
3.12.00.04.61.13.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$175.8620.66% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.24
Hold$126.4924.01% Upside

Current Analyst Ratings

Latest JNJ and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$169.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$168.00 ➝ $167.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$180.00 ➝ $170.00
4/17/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$181.00 ➝ $175.00
4/15/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
4/11/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
4/9/2024
Moderna, Inc. stock logo
MRNA
Moderna
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$125.00
4/1/2024
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/28/2024
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$125.00
3/28/2024
Moderna, Inc. stock logo
MRNA
Moderna
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
3/13/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$215.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$85.16B4.12$13.79 per share10.57$28.57 per share5.10
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B5.70N/AN/A$36.33 per share2.81

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$35.15B$16.049.0913.272.4045.26%36.43%15.01%7/18/2024 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$12.41N/AN/AN/A-68.84%-10.23%-7.70%5/2/2024 (Confirmed)

Latest JNJ and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.36N/A+$3.36N/AN/AN/A  
4/16/2024Q1 24
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.64$2.71+$0.07$3.22$21.39 billion$21.38 billion    
2/22/2024Q4 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$0.78$0.55+$1.33$0.55$2.53 billion$2.80 billion    
1/23/202412/31/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.28$2.29+$0.01$2.91$21.02 billion$21.40 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.763.27%+5.70%29.68%62 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A

Latest JNJ and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/16/2024
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.243.36%5/20/20245/21/20246/4/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.38
1.16
0.91
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.42
3.36

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
131,9002.41 billion2.41 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600382.88 million322.77 millionOptionable

JNJ and MRNA Headlines

SourceHeadline
Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 15,000 SharesModerna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 15,000 Shares
insidertrades.com - April 18 at 6:16 AM
Moderna, Inc. (MRNA)Moderna, Inc. (MRNA)
finance.yahoo.com - April 17 at 11:03 PM
Stephen Hoge Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) StockStephen Hoge Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock
marketbeat.com - April 17 at 3:28 PM
Moderna Options Trading: A Deep Dive into Market SentimentModerna Options Trading: A Deep Dive into Market Sentiment
benzinga.com - April 17 at 1:02 PM
Africa CDC blasts Moderna after it halts plans to build vaccine plant in KenyaAfrica CDC blasts Moderna after it halts plans to build vaccine plant in Kenya
fiercepharma.com - April 17 at 1:02 PM
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
finance.yahoo.com - April 17 at 8:02 AM
Sumitomo Mitsui Trust Holdings Inc. Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)Sumitomo Mitsui Trust Holdings Inc. Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)
marketbeat.com - April 17 at 6:09 AM
Pfizer, BioNTech Get Legal Pause in Moderna’s COVID-19 Vaccine Patent LawsuitPfizer, BioNTech Get Legal Pause in Moderna’s COVID-19 Vaccine Patent Lawsuit
biospace.com - April 16 at 12:00 PM
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should KnowModerna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know
zacks.com - April 16 at 10:05 AM
2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential2 Artificial Intelligence (AI) in Healthcare Stocks to Buy and Hold for Great Long-Term Potential
fool.com - April 16 at 4:55 AM
Africa CDC calls out Moderna for abandoning vaccine equity commitmentAfrica CDC calls out Moderna for 'abandoning' vaccine equity commitment
devex.com - April 15 at 8:59 PM
Pfizer, BioNTech win pause in patent infringement case from rival ModernaPfizer, BioNTech win pause in patent infringement case from rival Moderna
fiercepharma.com - April 15 at 8:59 PM
Granite Bay Wealth Management LLC Sells 11,400 Shares of Moderna, Inc. (NASDAQ:MRNA)Granite Bay Wealth Management LLC Sells 11,400 Shares of Moderna, Inc. (NASDAQ:MRNA)
marketbeat.com - April 14 at 12:00 PM
Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,606,800.00 in StockModerna, Inc. (NASDAQ:MRNA) Director Sells $1,606,800.00 in Stock
americanbankingnews.com - April 14 at 4:20 AM
Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 SharesModerna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares
insidertrades.com - April 13 at 7:07 AM
Moderna (NASDAQ:MRNA) Rating Reiterated by Needham & Company LLCModerna (NASDAQ:MRNA) Rating Reiterated by Needham & Company LLC
americanbankingnews.com - April 13 at 6:06 AM
Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells 15,000 Shares of StockInsider Selling: Moderna, Inc. (NASDAQ:MRNA) Director Sells 15,000 Shares of Stock
marketbeat.com - April 12 at 9:27 PM
Moderna drops plans to construct mRNA facility in Kenya, cites low vaccine demandModerna drops plans to construct mRNA facility in Kenya, cites low vaccine demand
capitalfm.co.ke - April 12 at 10:12 AM
Moderna pauses plans to build mRNA facility in KenyaModerna pauses plans to build mRNA facility in Kenya
pharmaceutical-technology.com - April 12 at 10:12 AM
1 New Green Flag for Moderna and Merck Stock1 New Green Flag for Moderna and Merck Stock
fool.com - April 12 at 8:45 AM
Moderna Betrays Africa, Says AHFModerna Betrays Africa, Says AHF
businesswire.com - April 11 at 11:18 PM
Moderna (MRNA) Stock Dips While Market Gains: Key FactsModerna (MRNA) Stock Dips While Market Gains: Key Facts
zacks.com - April 11 at 7:06 PM
Moderna (NASDAQ:MRNA) Postpones Plans of Vaccine Plant in KenyaModerna (NASDAQ:MRNA) Postpones Plans of Vaccine Plant in Kenya
msn.com - April 11 at 6:52 PM
Moderna pauses Kenya plant plans as COVID vaccine demand wanesModerna pauses Kenya plant plans as COVID vaccine demand wanes
reuters.com - April 11 at 6:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.